Steve Becker, Chief Commercial Officer, featured in article considering the key ethical and regulatory considerations in gene editing technologies.

Steve Becker, Chief Commercial Officer, Broken String Biosciences

Gene editing therapies have already made a tremendous public impact, most recently with the N-of-1 CRISPR-edited gene therapy that was developed, cleared for clinical use by FDA, and treated a patient in under 8 months. The speed was impressive, but about half of that time was tied to ensuring the therapy is safe.

Stakeholders are fully invested in ensuring these therapies are safe. FDA held one CRISPR clinical program for a year until its sponsor could characterize its unintended off-target edits to understand the drug’s risks. But during the delay, the company lost about $1 billion in market capitalization.

Until recently, companies have struggled to demonstrate safety, often spending months developing a bespoke informatics pipeline to ascertain even limited data on off-target gene edits. A gold standard is now emerging with technology that can accurately identify off-target editing through characterization of double stranded breaks in DNA — in depth and within days. Such tools will underpin the safe growth of gene editing therapies.

Read the full article “What are the key ethical and regulatory considerations as gene editing technologies advance toward widespread clinical use?” here.

Learn more about INDUCE-seq®

NEWS

All News

  • Broken String Biosciences’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing 

    Broken String Biosciences’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing 

    Cambridge, UK, 18 October 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing…

    Read more

  • Broken String Biosciences Closes $15M Series A Funding Round

    Broken String Biosciences Closes $15M Series A Funding Round

    Cambridge, UK, 18 September 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from…

    Read more

  • Broken String Biosciences joins Campus

    Broken String Biosciences joins Campus

    Cell & gene therapies based on genome editing technologies such as CRISPR-Cas9 are positioned to become a new generation of transformative therapeutics, with the ability to correct disease at the genetic level. Because they directly alter our DNA and have the propensity to go ‘off-target’, assessing whether these therapies are safe for patients is extremely…

    Read more